Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major

Haematologica

Volumn 97, Issue 6, 2012, Pages 842-848

  Pennell, Dudley J ^a   Porter, John B ^b   Cappellini, Maria Domenica ^c   Chan, Lee Lee ^d   El Beshlawy, Amal ^e   Aydinok, Yesim ^f   Ibrahim, Hishamshah ^g   Li, Chi Kong ^h   Viprakasit, Vip ⁱ   Elalfy, Mohsen S ^j   Kattamis, Antonis ^k   Smith, Gillian ^a   Habr, Dany ^l   Domokos, Gabor ^l   Roubert, Bernard ^l   Taher, Ali ^m  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^e CAIRO UNIVERSITY   (Egypt)

^f EGE UNIVERSITY   (Turkey)

^g HOSPITAL KUALA LUMPUR   (Malaysia)

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

ⁱ MAHIDOL UNIVERSITY   (Thailand)

^j AIN SHAMS UNIVERSITY   (Egypt)

^k UNIVERSITY OF ATHENS   (Greece)

^l NOVARTIS PHARMA AG   (Switzerland)

^m AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

more..

Author keywords

thalassemia major; Deferasirox; Iron chelation; Myocardial T2

Indexed keywords

DEFERASIROX; IRON;

ADOLESCENT; ADULT; ARTICLE; BETA THALASSEMIA; CARDIOVASCULAR MAGNETIC RESONANCE; CHILD; CHRONIC SINUSITIS; CREATININE CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMUR FRACTURE; FERRITIN BLOOD LEVEL; GASTRITIS; HEART ABSCESS; HEART ATRIUM FIBRILLATION; HEART HEMOSIDEROSIS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; RHEUMATIC FEVER; SCHOOL CHILD; SIDE EFFECT; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; BENZOATES; BETA-THALASSEMIA; BLOOD TRANSFUSION; CARDIOMYOPATHIES; CHELATION THERAPY; CHILD; DRUG ADMINISTRATION SCHEDULE; HEART; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LONGITUDINAL STUDIES; MAGNETIC RESONANCE ANGIOGRAPHY; TRIAZOLES;

EID: 84862141974     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.049957     Document Type: Article

References (27)

1. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, et al. Survival and causes of death in thalassaemia major. Lancet. 1989;2(8653):27-30.
2. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-93.
3. Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative Magnetic Resonance Imaging. Haematologica. 2011; 96(1):41-7.
4. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet. 2002;360(9332): 516-20.
5. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004;127(3):348-55.
6. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738-44.
7. Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in c-thalassemia. Blood. 2010;115(12):2364-71.
8. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, et al. Continued improvement in myocardial T2* over 2 years of deferasirox therapy in othalassemia major patients with cardiac iron overload. Haematologica. 2011;96 (1):48-54.
9. Pepe A, Lombardi M, Positano V, Cracolici E, Capra M, Malizia R, et al. Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. Eur J Haematol. 2006;76(3):183-92.
10. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(4):1876-84.
11. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001; 22(23):2171-9.
12. Alpendurada F, Carpenter J-P, Deac M, Kirk P, Walker JM, Porter JB, et al. Relation of myocardial T2* to right ventricular function in thalassaemia major. Eur Heart J. 2010;31(13):1648-54.
13. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961-8.
14. Carpenter J-P, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, et al. On T2* Magnetic Resonance and Cardiac Iron. Circulation. 2011;23(14):1519-28.
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
16. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247-54.
17. Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P, Glynos T, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood. 2010;116(4):537-43.
18. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous i-thalassemia. N Engl J Med. 1994; 331(9):574-8.
19. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica. 2003;88(5):489-96.
20. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. Blood. 2006;107:3733-7.
21. Ladis V, Chouliaras G, Berdoukas V, Moraitis P, Zannikos K, Berdoussi E, et al. Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek unit. Eur J Haematol. 2010;84(5):335-44.
22. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008;10:12.
23. Kolnagou A, Kleanthous M, Kontoghi-orghes GJ. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy. Eur J Haematol. 2010;85(5):430-8.
24. Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, et al. Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial. Am J Hematol. 2010;85(10):818-9.
25. Kakhlon O, Manning H, Breuer W, Melamed-Book N, Lu C, Cortopassi G, et al. Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood. 2008;112(13):5219-27.
26. Pennell DJ, Carpenter J-P, Roughton M, Cabantchik IZ. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. Cardiovasc Magn Reson. 2011; 13(1):45.
27. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with o-thalassemia. Blood. 2006;107(9):3455-62.